ACAD Stock Soars as US Court Rules in Favor of Key Nuplazid Patent

Core Viewpoint - Acadia Pharmaceuticals' shares increased by 26.5% following a favorable ruling from the U.S. District Court regarding the patent for its lead drug, Nuplazid, which protects the company from generic competition until 2038 [1][3]. Company Performance - Nuplazid is the only FDA-approved treatment for hallucinations and delusions associated with Parkinson's disease psychosis in the U.S. [2] - In Q1 2025, Nuplazid generated $159.7 million in revenue, marking a 23% year-over-year increase driven by volume growth [3]. - Year-to-date, Acadia's shares have risen by 21.3%, contrasting with a 6.9% decline in the industry [4]. Product Portfolio - Acadia's other marketed drug, Daybue, approved for treating Rett syndrome, generated $84.6 million in revenue in Q1 2025, an 11% increase year-over-year [5]. - Daybue reached a record high of 954 unique patients receiving shipments in Q1 2025 [7]. Pipeline Developments - Acadia is awaiting EU regulatory approval for trofinetide to treat Rett syndrome, expected in Q1 2026 [8]. - The company anticipates top-line results from the phase III COMPASS PWS study of ACP-101 for Prader-Willi Syndrome in early Q4 2025, with plans to submit a regulatory application to the FDA in Q1 2026 [9]. - Enrollment for the phase II RADIANT study of ACP-204 for Alzheimer's disease psychosis is expected to be completed in Q1 2026, with top-line data anticipated in mid-2026 [10]. - Acadia and Saniona have completed the phase I study of ACP-711, which showed a strong safety profile, and are focusing on essential tremor as the lead indication [11][12].